$ATRA Новость достойная ракеты 🚀 #туземун #atra Atara Biotherapeutics, Inc. (Nasdaq: ATRA) First presentation of transcriptional data for tab-cel® demonstrates consistency of the product’s activation profile irrespective of donor and consistent enrichment of receptors targeting EBV-driven diseases Atara partnered with CareDx ­­on an innovative testing solution that enables detection and quantification of non-engineered allogeneic T-cell therapies and establishes this as a sensitive and precise method for use in ATA188 clinical development Six posters support Atara’s novel allogeneic EBV T-cell platform